Mola hidatiforme parcial e completa: características clínicas e histológicas

• Autor(a) principal: Almeida, Larissa Oliveira Galindo
• Data de Publicação: 2019
• Outros Autores: Sousa, Edson de Macedo, Ribeiro, Ana Carolina Montes, Cavalcante, Diane Isabelle Magno, Feitosa, Francisco Edson Lucena, Coelho, Raquel Autran
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
• Texto Completo: http://www.repositorio.ufc.br/handle/riufc/48292
• topic: Doença Trofoblástica Gestacional; Gonadotropina Coriônica; Mola Hidatiforme

Introduction: Gestational trophoblastic disease (DTG) comprises a heterogeneous group of cell proliferation originating from the trophoblastic epithelium. It is divided into complete, partial, and gestational trophoblastic neoplasms. The hydatidiform mole occurs around 1:200-400 gestations in Brazil. Objective: To emphasize the clinical factors related to the histopathological findings of GFR among women from the states of Ceará, Brazil. Methods: A retrospective quantitative, descriptive, cross-sectional study was performed by means of medical records, totaling 203 patients with confirmed histopathological diagnosis between 2012 and 2015. Clinical-epidemiological and laboratory data were evaluated for cases of complete hydatidiform mole (MHC) and partial hydatidiform mole (MHP). Results: 203 cases of gestational trophoblastic disease, 49.2% cases of MHC and 49.7% of MHP were identified. There was no statistically significant difference for age, parity, recurrence of bleeding, presence of hypertension, type of bleeding at admission, vesicle elimination, ovarian cytorutinic cysts and evolution for gestational trophoblastic neoplasia (GTN) among women with MHC and MHP. The presence of bleeding at the time of hospitalization was observed in 76.9% in MHC cases and 85.5% in MHP cases. 14.3% of MHC cases and 12.1% of MHP cases progressed to NTG. Conclusion: There was no statistically significant difference between clinical and epidemiological factors for women with MHC and MHP.